Outcomes in splenic marginal zone lymphoma: Analysis of 107 patients treated in British Columbia

British Journal of Haematology

Volumn 169, Issue 4, 2015, Pages 520-527

  Xing, Katharine H ^a   Kahlon, Amrit ^b   Skinnider, Brian F ^c   Connors, Joseph M ^c   Gascoyne, Randy D ^c   Sehn, Laurie H ^c   Savage, Kerry J ^c   Slack, Graham W ^c   Shenkier, Tamara N ^c   Klasa, Richard ^c   Gerrie, Alina S ^c,d   Villa, Diego ^c  

^a British Columbia Cancer Agency Vancouver Island Centre   (Canada)

^b SURREY MEMORIAL HOSPITAL   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Chemotherapy; Rituximab; Splenectomy; Splenic marginal zone lymphoma; Transformation

Indexed keywords

ANTIVIRUS AGENT; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; CANADA; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; FAILURE FREE SURVIVAL; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; TREATMENT OUTCOME; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FOLLOW UP; LYMPHOMA, B-CELL, MARGINAL ZONE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RETROSPECTIVE STUDY; SPLENIC NEOPLASMS; SURVIVAL RATE; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRITISH COLUMBIA; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPLENECTOMY; SPLENIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 84928431367     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13320     Document Type: Article

References (23)

1. Al-Tourah, A.J., Gill, K.K., Chhanabhai, M., Hoskins, P.J., Klasa, R.J., Savage, K.J., Sehn, L.H., Shenkier, T.N., Gascoyne, R.D. & Connors, J.M. (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26, 5165-5169.
2. Arcaini, L., Lazzarino, M., Colombo, N., Burcheri, S., Boveri, E., Paulli, M., Morra, E., Gambacorta, M., Cortelazzo, S., Tucci, A., Ungari, M., Ambrosetti, A., Menestrina, F., Orsucci, L., Novero, D., Pulsoni, A., Frezzato, M., Gaidano, G., Vallisa, D., Minardi, V., Tripodo, C., Callea, V., Baldini, L., Merli, F., Federico, M., Franco, V., Iannitto, E. & Linfomi Integruppo Italiano (2006) Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood, 107, 4643-4649.
3. Armitage, J.O. & Weisenburger, D.D. (1998) New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 16, 2780-2795.
4. Bennett, M. & Schechter, G.P. (2010) Treatment of splenic marginal zone lymphoma: splenectomy versus Rituximab. Seminars in Hematology, 47, 143-147.
5. Bennett, M., Yegena, S., Dave, H.P. & Schechter, G.P. (2008) Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematological Oncology, 26, 114.
6. Berger, F., Felman, P., Thieblemont, C., Pradier, T., Baseggio, L., Bryon, P.A., Salles, G., Callet-Bauchu, E. & Coiffier, B. (2000) Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood, 95, 1950-1956.
7. Cervetti, G., Galimberti, S., Pelosini, M., Ghio, F., Cecconi, N. & Petrini, M. (2013) Significant efficacy of 2-Chlorodeoxyadenosine{+/-} Rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 24, 2434-2438.
8. Else, M., Marin-Niebla, A., de la Cruz, F., Batty, P., Rios, E., Dearden, C.E., Catovsky, D. & Matutes, E. (2012) Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. British Journal of Haematology, 159, 322-328.
9. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B. & Gatter, K.C. (1994) A Revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
10. Hermine, O., Lefrere, F., Bronowicki, J.P., Mariette, X., Jondeau, K., Eclache-Saudreau, V., Delmas, B., Valensi, F., Cacoub, P., Brechot, C., Varet, B. & Troussard, X. (2002) Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. The New England Journal of Medicine, 347, 89-94.
11. Iannitto, E., Ambrosetti, A., Ammatuna, E., Colosio, M., Florena, A.M., Tripodo, C., Minardi, V., Calvaruso, G., Mitra, M.E., Pizzolo, G., Menestrina, F. & Franco, V. (2004) Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer, 101, 2050-2057.
12. Kalpadakis, C., Pangalis, G.A., Vassilakopoulos, T.P., Sachanas, S. & Angelopoulou, M.K. (2013) Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? Leukemia & Lymphoma, 55, 1463-1470.
13. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
14. Lenglet, J., Traulle, C., Mounier, N., Benet, C., Munoz-Bongrand, N., Amorin, S., Noguera, M.E., Traverse-Glehen, A., Ffrench, M., Baseggio, L., Felman, P., Callet-Bauchu, E., Brice, P., Berger, F., Salles, G., Briere, J., Coiffier, B. & Thieblemont, C. (2014) Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leukemia & Lymphoma, 55, 1854-1860.
15. Matutes, E., Morilla, R., Owusu-Ankomah, K., Houlihan, A. & Catovsky, D. (1994) The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood, 83, 1558-1562.
16. Matutes, E., Oscier, D., Montalban, C., Berger, F., Callet-Bauchu, E., Dogan, A., Felman, P., Franco, V., Iannitto, E., Mollejo, M., Papadaki, T., Remstein, E.D., Salar, A., Sole, F., Stamatopoulos, K., Thieblemont, C., Traverse-Glehen, A., Wotherspoon, A., Coiffier, B. & Piris, M.A. (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia, 22, 487-495.
17. Montalban, C., Abraira, V., Arcaini, L., Domingo-Domenech, E., Guisado-Vasco, P., Iannitto, E., Mollejo, M., Matutes, E., Ferreri, A., Salar, A., Rattotti, S., Carpaneto, A., Perez Fernandez, R., Bello, J.L., Hernandez, M., Caballero, D., Carbonell, F. & Piris, M.A. & Splenic Marginal Zone Lymphoma Study Group. (2012) Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. British Journal of Haematology, 159, 164-171.
18. Mulligan, S.P., Matutes, E., Dearden, C. & Catovsky, D. (1991) Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. British Journal of Haematology, 78, 206-209.
19. Parry-Jones, N., Matutes, E., Gruszka-Westwood, A.M., Swansbury, G.J., Wotherspoon, A.C. & Catovsky, D. (2003) Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. British Journal of Haematology, 120, 759-764.
20. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiam, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon.
21. Thieblemont, C., Felman, P., Callet-Bauchu, E., Traverse-Glehen, A., Salles, G., Berger, F. & Coiffier, B. (2003) Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. The Lancet Oncology, 4, 95-103.
22. Troussard, X., Valensi, F., Duchayne, E., Garand, R., Felman, P., Tulliez, M., Henry-Amar, M., Bryon, P.A. & Flandrin, G. (1996) Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). British Journal of Haematology, 93, 731-736.
23. Tsimberidou, A.M., Catovsky, D., Schlette, E., O'Brien, S., Wierda, W.G., Kantarjian, H., Garcia-Manero, G., Wen, S., Do, K.A., Lerner, S. & Keating, M.J. (2006) Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with Rituximab with or without chemotherapy or chemotherapy alone. Cancer, 107, 125-135.